PATENT CLAIM ANALYSIS

Application Number: 15957122
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["514", "009600"]

Abstract:
The invention relates to treatment and prevention of heart failure in a mammal. The invention provides a dosing regimen whereby the therapeutic benefits conferred by administration of peptide comprising an epidermal growth factor-like domain, e.g., a neuregulin such as glial growth factor 2 (GGF2) or a functional fragment thereof, are maintained and/or enhanced, while concomitantly minimizing any potential side effects.

Claim (Index 7):
The method of  claim 2 , wherein the dosing regimen comprises the steps of:\n a. administering an initial dose of the peptide in the range of about 0.005 mg/kg bodyweight to about 0.015 mg/kg bodyweight; b. thereafter administering a second dose of the peptide that is 2-fold to 3-fold above the previous dose; and c. repeating step b) until a maximum therapeutic dose is reached, wherein the maximum therapeutic dose does not elicit an adverse event in the subject, and wherein the doses are administered on an interval of at least 24 hours.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 91.0
- Lexical Diversity: 1.19298
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13904654', '14928124', '13059206', '15357586', '14844475']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7725333305059112
- 35 USC 102 Novelty (BERT): 0.5564658620814377
- Combined Prediction Score: 0.7509265836634639
- Mean Citation Score: 367.206068
- Max Citation Score: 440.68204
- Similarity Product: 267.8708436321425

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test